This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: August 31, 2009
Last updated: March 6, 2012
Last verified: March 2012
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 in Asian cancer patients, and to provide safety data in terms of drug-related adverse events.

Condition Intervention Phase
Neoplasms Drug: BI 6727 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Maximum tolerated dose [ Time Frame: 3 weeks ]

Secondary Outcome Measures:
  • Adverse event [ Time Frame: 3 weeks after last administration of BI 6727 ]
  • Progression-free survival [ Time Frame: about 6 months ]
  • Response duration [ Time Frame: about 6 months ]
  • objective response [ Time Frame: Every other course from entry to end-of-treatment ]
  • pharmacokinetics [ Time Frame: Selected time points during first 4 weeks ]

Enrollment: 59
Study Start Date: August 2009
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 6727
Schedule A
Drug: BI 6727
Dose level 1


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Patients with histologically or cytologically confirmed diagnosis of advanced solid cancer
  2. Age 18 years or older
  3. Written informed consent
  4. Eastern Cooperative Oncology Group (ECOG) performance score 2 or less

Exclusion criteria:

  1. Serious illness or concomitant non-oncological disease.
  2. Pregnancy or breast feeding
  3. Active infectious disease
  4. Absolute neutrophil count less than 1,500/cubic millimeter
  5. Platelet count less than 100,000/cubic millimeter
  6. Bilirubin greater than 1.5 mg/dL (> 26 µmol/L, SI unit equivalent)
  7. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal
  8. Serum creatinine greater than 1.5x ULN.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00969553

1230.16.886002 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1230.16.886001 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT00969553     History of Changes
Other Study ID Numbers: 1230.16
Study First Received: August 31, 2009
Last Updated: March 6, 2012 processed this record on August 18, 2017